Assessment of multidrug resistance, clonality and virulence in non-PCV-13 Streptococcus pneumoniae serotypes in Canada, 2011-13

The Journal of Antimicrobial Chemotherapy
Alyssa R GoldenGeorge G Zhanel

Abstract

Serotype replacement in Streptococcus pneumoniae following the implementation of a new vaccine has been associated with the emergence of non-vaccine serotypes as prominent causes of invasive pneumococcal disease (IPD). The aim of this study was to characterize specific non-PCV-13 serotypes 15A, 22F, 33F and 35B from IPD, isolated in Canada post-PCV-13 introduction in 2010. Of 3802 IPD isolates collected from across Canada in 2011-13, 18.4% were found to be serotypes 15A, 22F, 33F and 35B. These 699 isolates were subjected to antimicrobial susceptibility testing, PFGE, MLST, molecular detection of pneumococcal pili and comparison with Pneumococcal Molecular Epidemiology Network (PMEN) clones. This study demonstrated clonal spread of specific STs, including MDR ST63 and its Sweden(15A)-25-related variants, the increasingly common ST433 and a variant of piliated, penicillin-non-susceptible ST558, related to PMEN clone Utah(35B)-24 (ST377). New STs of serotype 33F were identified. Several potential capsular switching events were identified within these serotypes. Non-PCV-13 serotype 22F is increasing in Canada through the rapid clonal expansion of ST433. Numerous new STs associated with serotype 33F indicate the potential divergenc...Continue Reading

References

Feb 17, 2006·Proceedings of the National Academy of Sciences of the United States of America·M A BarocchiB Henriques-Normark
Nov 21, 2007·PLoS Pathogens·Angela B BrueggemannBernard Beall
Jan 1, 2009·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sandra S RichterGary V Doern
Dec 2, 2009·The Journal of Infectious Diseases·Tamara PilishviliUNKNOWN Active Bacterial Core Surveillance/Emerging Infections Program Network
Feb 24, 2010·The Journal of Infectious Diseases·Robert E GertzUNKNOWN Active Bacterial Core Surveillance Team
May 29, 2010·Emerging Infectious Diseases·Dorothea ZähnerDavid S Stephens
Dec 30, 2011·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Heather J AdamGeorge G Zhanel
Jul 26, 2012·Canadian Journal of Microbiology·Walter H B DemczukUNKNOWN Canadian Public Health Laboratory Network
Oct 9, 2013·The Medical Journal of Australia·Janet E StrachanGeoffrey G Hogg

❮ Previous
Next ❯

Citations

Apr 14, 2016·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Venkata R DuvvuriJonathan B Gubbay
Nov 17, 2016·Journal of Clinical Microbiology·Liset OlarteKristina G Hultén
Jul 10, 2018·The Journal of Antimicrobial Chemotherapy·Alyssa R GoldenUNKNOWN Canadian Antimicrobial Resistance Alliance (CARA)

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.